Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases.

MLA

Sidiras, P., et al. “Antibodies against Carbamylated Proteins: Prevalence and Associated Disease Characteristics in Belgian Patients with Rheumatoid Arthritis or Other Rheumatic Diseases.” Scandinavian Journal of Rheumatology, vol. 50, no. 2, Mar. 2021, pp. 118–23. EBSCOhost, https://doi.org/10.1080/03009742.2020.1798500.

APA

Sidiras, P., Spruyt, D., Gangji, V., Imbault, V., Sokolova, T., Durez, P., Communi, D., Rasschaert, J., & Badot, V. (2021). Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases. Scandinavian Journal of Rheumatology, 50(2), 118–123. https://doi.org/10.1080/03009742.2020.1798500

Chicago

Sidiras, P, D Spruyt, V Gangji, V Imbault, T Sokolova, P Durez, D Communi, J Rasschaert, and V Badot. 2021. “Antibodies against Carbamylated Proteins: Prevalence and Associated Disease Characteristics in Belgian Patients with Rheumatoid Arthritis or Other Rheumatic Diseases.” Scandinavian Journal of Rheumatology 50 (2): 118–23. doi:10.1080/03009742.2020.1798500.